Prot #CTIN816B12202: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Parallel-Group, Dose-Finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 via a Single Intravenous Infusion in the Treatment of Participants wi

Project: Research project

Project Details

StatusActive
Effective start/end date1/1/24 → 12/31/28

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CTIN816B12202)